About us
An active biocell portfolio development company
Takura is active in regenerative medicine with mesenchymal stromal cells (MSC) as well as in immuno oncology (TIL). The aim is to develop advanced cell therapies and make them accessible to people in need of treatments.
The operations are conducted by subsidiaries and Takura is currently the majority owner of three holdings; StromaBio (human MSC applications), Cellavos (veterinary MSC applications) and CuraCell (TIL immuno oncology). Takura is also the co-founder of Cellcolabs (MSC production) together with Norrsken Foundation. Cellcolabs was spun off to Takura shareholders in 2023.